Expression of serum miR‑27b and miR‑451 in patients with congenital heart disease associated pulmonary artery hypertension and risk factor analysis

Long,Leiwang; Xiao,Yunbin; Yin,Xiaocheng; Gao,Shunli; Zhou,Lingzhi; Liu,Hui

doi:10.3892/etm.2020.9042

Expression of serum miR‑27b and miR‑451 in patients with congenital heart disease associated pulmonary artery hypertension and risk factor analysis

Authors:
- Leiwang Long
- Yunbin Xiao
- Xiaocheng Yin
- Shunli Gao
- Lingzhi Zhou
- Hui Liu
View Affiliations

Affiliations: Paediatric Intensive Care Unit, The First Affiliated Hospital of the University of South China, Hengyang, Hunan 421000, P.R. China, Department of Cardiology, Hunan Children's Hospital, Changsha, Hunan 410007, P.R. China, Department of Pediatrics, The First Affiliated Hospital of the University of South China, Hengyang, Hunan 421000, P.R. China
Published online on: July 24, 2020 https://doi.org/10.3892/etm.2020.9042
Pages: 3196-3202
Copyright: © Long et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study investigated expression of serum miR-27b and miR-451 in patients with congenital heart disease associated pulmonary arterial hypertension (CHD‑PAH), and analyzed the risk factors of CHD‑PAH. A total of 114 patients with CHD admitted to the First Affiliated Hospital of the University of South China were recruited and allocated into a study group (61 patients with PAH) and a control group (53 patients without PAH). Reverse transcription‑polymerase chain reaction (RT‑PCR) was employed for the qualification of serum miR‑27b and miR‑451, and an automatic biochemical analyzer was used for the measurement of biochemical indexes in peripheral blood, and enzyme‑linked immunosorbent assay (ELISA) for the detection of serum brain natriuretic peptide (BNP) and asymmetric dimethylarginine (ADMA). The patients with CHD‑PAH showed higher serum miR‑27b, BNP and ADMA but lower miR‑451 than the controls. Serum miR‑27b was positively correlated with mean pulmonary artery pressure (mPAP), BNP and ADMA, whereas serum miR‑451 was negatively correlated with them. The combined detection of miR‑27b and miR‑451 was more valuable than a single detection in the diagnosis of CHD‑PAH. Logistic regression analysis showed that ADMA, miR‑27b, miR‑451 and ventricular septal defect (VSD) were independent risk factors for CHD‑PAH. In conclusion, miR‑27b is highly expressed and miR‑451 and the expression is low in patients with CHD‑PAH. miR‑27b and miR‑451 are significantly correlated with BNP, ADMA, and the severity of the disease. The combination of miR‑27b and miR‑451 has high diagnostic value and can be used as a biomarker for the diagnosis and assessment of CHD‑PAH. CHD‑PAH is common in children with CHD, which poses a serious threat to the life and safety. At present, there are no effective methods for its early diagnosis and treatment. MicroRNAs (miRNAs, miRs) have been found to be closely related to the pathogenesis of CHD‑PAH. In this study, miR‑27b and miR‑451 with differential expression in CHD‑PAH were evaluated, and it was found that they were of great significance in the diagnosis and assessment of CHD‑PAH.

View Figures

View References

1	Chew JD, Loyd JE and Austin ED: The genetics of pulmonary arterial hypertension. Semin Respir Crit Care Med. 38:585–595. 2017.PubMed/NCBI View Article : Google Scholar
2	van der Feen DE, Bartelds B, de Boer RA and Berger RM: Pulmonary arterial hypertension in congenital heart disease: Translational opportunities to study the reversibility of pulmonary vascular disease. Eur Heart J. 38:2034–2041. 2017.PubMed/NCBI View Article : Google Scholar
3	Roberts KE, McElroy JJ, Wong WP, Yen E, Widlitz A, Barst RJ, Knowles JA and Morse JH: BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J. 24:371–374. 2004.PubMed/NCBI View Article : Google Scholar
4	Sun ML, Cheng CY, Wu DC, Zhao QH, Liu QQ, Jiang R, Jiang X and Jing ZC: Long-term survival of patients with repaired congenital heart disease associated pulmonary arterial hypertension (CHD-PAH) in the modern management era. Eur Heart J. 34 (Suppl 1)(P287)2013.
5	Sun ML, Cheng CY, Wu DC, Zhang R, Zhang X, Xu XQ, Sun K, Zhao QH, Wang X-J, Jiang R, et al: Survival of patients with repaired CHD-PAH in the modern management era. J Am Coll Cardiol. 63(A1484)2014.
6	Boucherat O, Potus F and Bonnet S: microRNA and pulmonary hypertension. Adv Exp Med Biol. 888:237–252. 2015.PubMed/NCBI View Article : Google Scholar
7	Grant JS: The role of microRNA in the development of pulmonary arterial hypertension: Studies in cell culture and animal models. University of Glasgow, p263, 2014.
8	Hailong D and Yin XL: GW25-e2158. The changes of plasma miR-18a, miR-27b, miR-130a, miR-204 in patients with pulmonary arterial hypertension due to congenital heart disease. J Am Coll Cardiol. 64 (Suppl 16):C190. 2014.
9	Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, Lu R, White K, Mair KM, McClure JD, Southwood M, et al: A role for miR-145 in pulmonary arterial hypertension: Evidence from mouse models and patient samples. Circ Res. 111:290–300. 2012.PubMed/NCBI View Article : Google Scholar
10	Wang X, Zhu H, Zhang X, Liu Y, Chen J, Medvedovic M, Li H, Weiss MJ, Ren X and Fan GC: Loss of the miR-144/451 cluster impairs ischaemic preconditioning-mediated cardioprotection by targeting Rac-1. Cardiovasc Res. 94:379–390. 2012.PubMed/NCBI View Article : Google Scholar
11	Grymuza M, Małaczyńska-Rajpold K, Jankiewicz S, Siniawski A, Grygier M, Mitkowski P, Kałużna-Oleksy M, Lesiak M, Mularek-Kubzdela T and Araszkiewicz A: Right heart catheterization procedures in patients with suspicion of pulmonary hypertension - experiences of a tertiary center. Postepy Kardiol Interwencyjnej. 13:295–301. 2017.PubMed/NCBI View Article : Google Scholar
12	Stephan R, Ghofrani H, Beghetti M, Ivy D, Fritsch A, Weimann G, Saleh S, Apitz C and Frey R: Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies. BMC Pharmacol Toxicol. 16 (Suppl 1)(A79)2015.PubMed/NCBI View Article : Google Scholar
13	Chen IC and Dai ZK: Insight into pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD): Classification and pharmacological management from a pediatric cardiological point of view. Acta Cardiol Sin. 31:507–515. 2015.PubMed/NCBI View Article : Google Scholar
14	Chen W and Li S: Circulating microRNA as a novel biomarker for pulmonary arterial hypertension due to congenital heart disease. Pediatr Cardiol. 38:86–94. 2017.PubMed/NCBI View Article : Google Scholar
15	Zhao H, Guo Y, Sun Y, Zhang N and Wang X: miR-181a/b-5p ameliorates inflammatory response in monocrotaline-induced pulmonary arterial hypertension by targeting endocan. J Cell Physiol. 235:4422–4433. 2020.PubMed/NCBI View Article : Google Scholar
16	Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, et al: MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation. 116:258–267. 2007.PubMed/NCBI View Article : Google Scholar
17	Grant JS, Morecroft I, Dempsie Y, van Rooij E, MacLean MR and Baker AH: Transient but not genetic loss of miR-451 is protective in the development of pulmonary arterial hypertension. Pulm Circ. 3:840–850. 2013.PubMed/NCBI View Article : Google Scholar
18	Ma K, Zhao Q, Chen W, Zhang H, Li S, Pan X and Chen Q: Human lung microRNA profiling in pulmonary arterial hypertension secondary to congenital heart defect. Pediatr Pulmonol. 50:1214–1223. 2015.PubMed/NCBI View Article : Google Scholar
19	Wei C, Henderson H, Spradley C, Li L, Kim IK, Kumar S, Hong N, Arroliga AC and Gupta S: Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One. 8(e64396)2013.PubMed/NCBI View Article : Google Scholar
20	McLellan J, Heneghan CJ, Perera R, Clements AM, Glasziou PP, Kearley KE, Pidduck N, Roberts NW, Tyndel S, Wright FL, et al: B-type natriuretic peptide-guided treatment for heart failure. Cochrane Database Syst Rev: Dec 22, 2016 (Epub ahead of print). doi: 10.1002/14651858.CD008966.pub2.
21	Pruneda-Alvarez LG, Ruíz-Vera T, Ochoa-Martínez AC, Pérez-Vázquez FJ, González Palomo AK, Ilizaliturri-Hernández CA and Pérez-Maldonado IN: Plasma asymmetric dimethylarginine (ADMA) levels in Mexican women exposed to polycyclic aromatic hydrocarbons (PAHs): A preliminary study. Sci Total Environ. 572:1195–1202. 2016.PubMed/NCBI View Article : Google Scholar
22	Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH and Krom RA: Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 6:443–450. 2000.PubMed/NCBI View Article : Google Scholar
23	Sr GY: Evaluation of acute hemodymamic effect of inhaled iloprost in pulmonary artery hypertension with right heart catheterization. Cardiovasc Revasc Med. 10:197. 2009.
24	Song XW, Zou LL, Cui L, Li SH, Qin YW, Zhao XX and Jing Q: Plasma miR-451 echocardiography can be used as a reference for the diagnosis of pulmonary hypertension. Acta Pharmacol Sin. 39:1208–1216. 2018.PubMed/NCBI View Article : Google Scholar
25	Friedman WF: Proceedings of the National Heart, Lung, and Blood Institute Pediatric Cardiology Workshop: Pulmonary Hypertension. Pediatr Res. 20:811–824. 1986.PubMed/NCBI View Article : Google Scholar
26	Schuijt MT, Blok IM, Zwinderman AH, van Riel AC, Schuuring MJ, de Winter RJ, Duijnhouwer AL, van Dijk AP, Mulder BJ and Bouma BJ: Mortality in pulmonary arterial hypertension due to congenital heart disease: Serial changes improve prognostication. Int J Cardiol. 243:449–453. 2017.PubMed/NCBI View Article : Google Scholar